STOCK TITAN

Achilles Therapeutics Plc - ACHL STOCK NEWS

Welcome to our dedicated news page for Achilles Therapeutics Plc (Ticker: ACHL), a resource for investors and traders seeking the latest updates and insights on Achilles Therapeutics Plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Achilles Therapeutics Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Achilles Therapeutics Plc's position in the market.

Rhea-AI Summary
Achilles Therapeutics plc (ACHL) will be presenting at the 10th Annual Immuno-Oncology 360 Conference to discuss precision T cell therapies targeting clonal neoantigens for solid tumors. The presentation will be led by Sergio Quezada, PhD, the Chief Scientific Officer, and will take place in New York on February 29, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
conferences
-
Rhea-AI Summary
Achilles Therapeutics plc (NASDAQ: ACHL) announced the publication of a 'Comment' in Nature Cancer outlining the potential of neoantigen immunogenicity prediction and the limitations in the field. The company has developed AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.84%
Tags
none
-
Rhea-AI Summary
Achilles Therapeutics plc (NASDAQ: ACHL) announced its financial results for the quarter ended September 30, 2023, and recent business highlights. The company is on track to dose 15-20 patients with higher dose cNeT by year-end 2023. Clinical and translational science data update from the ongoing Phase I/IIa trials in NSCLC and melanoma expected in Q1 2024 with additional data available in mid-2024. The company has a strong cash position of $140 million to support operations through 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
earnings
Rhea-AI Summary
Achilles Therapeutics receives notice from Nasdaq regarding non-compliance with minimum bid price requirement for continued listing of ADSs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Achilles Therapeutics announces financial results for Q2 2023 and upcoming clinical data in Q4 2023 for its T cell therapies. The company also highlights the improved performance of its bioinformatics platform and the potential of its neoRanker™ tool. Achilles Therapeutics regains compliance with Nasdaq listing requirements. Cash position of $144 million supports operations through 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.9%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.38%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.18%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
conferences
Achilles Therapeutics Plc

Nasdaq:ACHL

ACHL Rankings

ACHL Stock Data

48.53M
18.23M
5.75%
53.42%
0.38%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United Kingdom
245 Hammersmith Road

About ACHL

achilles therapeutics’ mission is to develop next-generation, patient-specific therapies that harness the immune system to destroy cancer cells. the therapies will target truncal (also known as clonal) tumour neo-antigens, unique flags to the immune system present on the surface of every cancer cell. these truncal neo-antigens are created early in the cancer’s evolution and present on all cancer cells in an individual patient’s tumour but not on healthy cells, so could allow scientists to target and destroy tumours without harming healthy tissues. achilles therapeutics brings together four scientific founders with world leading expertise in the understanding of cancer evolution, bioinformatics and the development of immunotherapies.